MX2023006639A - Composiciones para aumentar la semivida de un agente terapeutico en ganado y metodos de uso. - Google Patents
Composiciones para aumentar la semivida de un agente terapeutico en ganado y metodos de uso.Info
- Publication number
- MX2023006639A MX2023006639A MX2023006639A MX2023006639A MX2023006639A MX 2023006639 A MX2023006639 A MX 2023006639A MX 2023006639 A MX2023006639 A MX 2023006639A MX 2023006639 A MX2023006639 A MX 2023006639A MX 2023006639 A MX2023006639 A MX 2023006639A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- life
- methods
- therapeutic agent
- livestock animals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063122365P | 2020-12-07 | 2020-12-07 | |
| PCT/US2021/061409 WO2022125355A1 (en) | 2020-12-07 | 2021-12-01 | Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006639A true MX2023006639A (es) | 2023-08-16 |
Family
ID=81848817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006639A MX2023006639A (es) | 2020-12-07 | 2021-12-01 | Composiciones para aumentar la semivida de un agente terapeutico en ganado y metodos de uso. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12103961B2 (https=) |
| EP (1) | EP4255933A4 (https=) |
| JP (1) | JP2023552456A (https=) |
| KR (1) | KR20230128283A (https=) |
| CN (1) | CN117043190A (https=) |
| AU (1) | AU2021397693A1 (https=) |
| CA (1) | CA3201120A1 (https=) |
| MX (1) | MX2023006639A (https=) |
| TW (1) | TW202237641A (https=) |
| WO (1) | WO2022125355A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119730881A (zh) * | 2022-08-05 | 2025-03-28 | 硕腾服务有限责任公司 | 牛抗体突变体 |
| KR20250084941A (ko) * | 2022-10-07 | 2025-06-11 | 조에티스 서비시즈 엘엘씨 | 돼지 항체 돌연변이체 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
| US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
| ES2142801T3 (es) | 1991-03-11 | 2000-05-01 | Univ Georgia Res Found | Clonacion y expresion de luciferasa de renilla. |
| EP0759170B1 (en) | 1993-09-10 | 2008-07-09 | The Trustees Of Columbia University In The City Of New York | Uses of green fluorescent protein |
| WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
| US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
| US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
| US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
| US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
| IL129767A0 (en) | 1996-12-12 | 2000-02-29 | Prolume Ltd | Apparatus and method for detecting and identifying infectious agents |
| JP2002507410A (ja) | 1998-03-27 | 2002-03-12 | プロルーム・リミテッド | ルシフェラーゼ、蛍光タンパク質、ルシフェラーゼおよび蛍光タンパク質をコードする核酸および、診断、高処理スクリーニングおよび新規アイテムにおけるその使用 |
| US7083784B2 (en) * | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| WO2005047327A2 (en) * | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| US20060074225A1 (en) * | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
| AU2005304624B2 (en) * | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| JP6322411B2 (ja) * | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| US20130129727A1 (en) | 2011-11-17 | 2013-05-23 | Nanjingjinsirui Science & Technology Biology Corporation | Methods and systems for increasing protein stability |
| KR20230143201A (ko) * | 2011-11-30 | 2023-10-11 | 추가이 세이야쿠 가부시키가이샤 | 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약 |
| NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| DK3484514T3 (da) * | 2016-05-23 | 2024-01-29 | Momenta Pharmaceuticals Inc | Compositions and methods related to engineered fc constructs |
| WO2018151841A1 (en) * | 2017-02-17 | 2018-08-23 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
| CA3120566C (en) * | 2017-04-07 | 2023-12-12 | Kookmin University Industry Academy Cooperation Foundation | Antibody fc variants for increased blood half-life |
| US20210388053A1 (en) * | 2018-10-18 | 2021-12-16 | Kindred Biosciences, Inc. | Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use |
| CN113544153B (zh) * | 2019-01-03 | 2024-12-10 | 因外泰克斯公司 | 用于增加治疗剂在犬中的半衰期的组合物及使用方法 |
| CN120590527A (zh) * | 2020-05-11 | 2025-09-05 | 因外泰克斯公司 | 用于增加治疗剂在犬中的半衰期的组合物和使用方法 |
| KR20230038522A (ko) * | 2020-07-10 | 2023-03-20 | 인베티엑스 인코포레이티드 | 고양이에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법 |
| JP2023551194A (ja) | 2020-11-20 | 2023-12-07 | ゾエティス・サービシーズ・エルエルシー | ウシ科動物抗体バリアント |
-
2021
- 2021-12-01 EP EP21904137.3A patent/EP4255933A4/en active Pending
- 2021-12-01 CA CA3201120A patent/CA3201120A1/en active Pending
- 2021-12-01 US US17/540,044 patent/US12103961B2/en active Active
- 2021-12-01 KR KR1020237021674A patent/KR20230128283A/ko active Pending
- 2021-12-01 JP JP2023534323A patent/JP2023552456A/ja active Pending
- 2021-12-01 CN CN202180092133.4A patent/CN117043190A/zh active Pending
- 2021-12-01 AU AU2021397693A patent/AU2021397693A1/en active Pending
- 2021-12-01 WO PCT/US2021/061409 patent/WO2022125355A1/en not_active Ceased
- 2021-12-01 MX MX2023006639A patent/MX2023006639A/es unknown
- 2021-12-06 TW TW110145549A patent/TW202237641A/zh unknown
-
2024
- 2024-08-27 US US18/816,282 patent/US20250197478A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250197478A1 (en) | 2025-06-19 |
| WO2022125355A1 (en) | 2022-06-16 |
| US12103961B2 (en) | 2024-10-01 |
| CA3201120A1 (en) | 2022-06-16 |
| CN117043190A (zh) | 2023-11-10 |
| AU2021397693A1 (en) | 2023-07-13 |
| JP2023552456A (ja) | 2023-12-15 |
| TW202237641A (zh) | 2022-10-01 |
| EP4255933A4 (en) | 2025-07-23 |
| US20220177549A1 (en) | 2022-06-09 |
| EP4255933A1 (en) | 2023-10-11 |
| KR20230128283A (ko) | 2023-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022014150A (es) | Composiciones para aumentar la semivida de un agente terapeutico en caninos y metodos de uso. | |
| WO2020142625A3 (en) | Compositions for increasing half-life of a therapeutic agent in canines and methods of use | |
| MX2023000500A (es) | Composiciones para aumentar la semivida de un agente terapeutico en felinos y modos de uso. | |
| MX2023006639A (es) | Composiciones para aumentar la semivida de un agente terapeutico en ganado y metodos de uso. | |
| MX2021004313A (es) | Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario. | |
| MY206158A (en) | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer | |
| CA3010621A1 (en) | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases | |
| MY208638A (en) | Anti-steap1 antigen-binding protein | |
| PH12020500648A1 (en) | Il-15 variants and uses thereof | |
| MX2025002974A (es) | Proteinas il-15/il-15ra de fusion a fc heterodimericas y usos de las mismas | |
| MX2020014296A (es) | Variantes de interleucina-2 y sus métodos de uso. | |
| PH12021551439A1 (en) | Irreversible inhibitors of menin-mll interaction | |
| EP4403635A3 (en) | Fusion protein comprising il-2 protein and cd80 protein, and use thereof | |
| PH12022550688A1 (en) | Immunocytokine comprising heterodimeric protein complex based on il-15/il-15r# | |
| MX2021010840A (es) | Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable. | |
| SA519401646B1 (ar) | الجلوبولينات المناعية واستخداماتها | |
| EA202192555A1 (ru) | Комбинированная терапия для лечения рака | |
| PE20200496A1 (es) | Virus de la enfermedad de newcastle y usos de los mismos | |
| EP1487493A4 (en) | CONJUGATES OF THERAPEUTIC OR CYTOTOXIC AGENTS AND BIOACTIVE PEPTIDES | |
| MX2020009639A (es) | Vacunas de peptídos contra interleucina-31. | |
| GB202006974D0 (en) | Chimaeric proteins and therapeutic agents | |
| MX2023012131A (es) | Construcciones de il-2. | |
| NZ801473A (en) | Lactam-modified polypeptide compounds | |
| MXPA05008704A (es) | Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas. | |
| EA201991015A1 (ru) | Модифицированные пептиды |